Short Bowel Syndrome – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Short Bowel Syndrome – Drugs In Development, 2024 report and make more profitable business decisions.
Short bowel syndrome is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. Symptoms include bloating, cramping, fatigue, heartburn, vomiting, weakness, and diarrhea. Complications of short bowel syndrome include malnutrition, peptic ulcers, kidney stones, and small intestinal bacterial overgrowth. Treatment includes vitamin and mineral supplements, antibiotics, proton pump inhibitors, and bile-salt binders.
The Short Bowel Syndrome drugs in development market research report provide comprehensive information on the therapeutics under development for Short Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Short Bowel Syndrome and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Short Bowel Syndrome | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 20 molecules, with 20 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Short Bowel Syndrome therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Short Bowel Syndrome pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Short Bowel Syndrome treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
9 Meters Biopharma IncAsahi Kasei Pharma Corp
Baxter International Inc
enGene Holdings Inc
Entera Bio Ltd
Hanmi Pharmaceuticals Co Ltd
Huons Global Co Ltd
ImmunoForge Co Ltd
Ironwood Pharmaceuticals Inc
Micelle BioPharma Inc
Napo Pharmaceuticals Inc
Napo Therapeutics SpA
OPKO Health Inc
Peg-Bio BioPharma Co Ltd
QuiaPEG Pharmaceuticals AB
Surrozen Inc
Tasly Pharmaceutical Group Co Ltd
Worphmed Srl
Zealand Pharma AS
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Short Bowel Syndrome reports